CNBC Stock Blog
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- 3 Software Stock Picks from Lazard's Senior Analyst
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
MOST SHARED
- No Thanksgiving Rest for Retailers in Sales Race
- Banks Play Down Dubai Exposure, Investors Still Wary
- UK's Darling to Downgrade 2009 Growth Forecast
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- More Asia Executives Resigned to Economy Flights: Survey
- Attraction of Switzerland to Businesses
- Acer Launches Android Phone, Says Targets on Track
- ING Prices Share Issue at Hefty Discount
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Car Insurance Scofflaws Raise Health Reform Doubt
- Rush Starts as Holiday Shopping Season Revs Up
- US Markets Bracing for Selloff on Dubai Debt Worries
- US Dollar Falls to 14-Year Low Against the Yen
- ING Prices Share Issue at Hefty Discount
- UK's Darling to Downgrade 2009 Growth Forecast
- Tommy Hilfiger's Estate in Conn. Sells for $20 Million
- Cheap Robotic Hamsters Are Holiday's Unlikely Craze
- Fannie Mae to Tighten Lending Standards: Report
RSS FEED
Text Size 
CNBC News Associate
Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months.
Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.
(See their picks and pans, below.)
“We found that the best time to invest was during the 'HillaryCare'" debate in the early 1990s, Sendek told CNBC. "And valuations haven’t gotten to the point since then until this year.”
“So we think it’s reasonable to invest across the board. Within the types of companies, I would argue for the smaller ones because I think there’s more upside.”
CNBC Investing Intelligence:
- Bookmark: Track the 30 Key Health Care Stocks
- S&P to Hit 1,200 in 3-6 Months: Strategist
- Art Cashin: Stocks Riding Jewish Holiday, Dollar, M&A
Sendek added that the smaller biotech firms are less likely to be affected by Washington’s health care reform discussions.
“When people don’t know anything other than there’s going to be reform, they sell first and ask questions later,” he said. “As we get details, it’s getting clearer that biotechs won’t be impacted as much.”
Schmidt said investors should look for good fundamental values, take into account the company’s future cash flows and buy those that are trading at discount to the market.
“Health care reform has kept a lot of investors at bay,” he said. “Whether health care reform happens or not, there’ll be money that comes back into biotech once it’s all decided.”
Schmidt’s Picks:
Biogen Idec [BIIB
Loading...
()
]
Alexion Pharmaceuticals [ALXN
Loading...
()
]
Schmidit’s Pans:
Celgene [CELG
Loading...
()
]
Sendek’s Picks:
Dendreon [DNDN
Loading...
()
]
ViroPharma [VPHM
Loading...
()
]
Acorda Therapeutics [ACOR
Loading...
()
]
______________________________
Disclosure:
No immediate information was available for Schmidt or Sendek.
______________________________
CNBC Slideshows:
______________________________
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes